Broad strategic collaboration leveraging combined immunology expertise and assets to develop and commercialize novel immunotherapies for the treatment of cancer and autoimmune diseases Celgene to make initial payment of approximately $1 billion which includes the purchase of ~9.1 million shares of Juno stock at $93.00 per share, with potential to increase its stake over time SUMMIT, N.J. & SEATTLE-- -- Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization of immunotherapies.